Business & Finance
Orphan Biovitrum reports Q1 2019 financial results
25 April 2019 - Sweden-based Orphan Biovitrum AB (publ) yesterday announced its financial results for the first quarter of 2019.The company reported total revenues of SEK3,265m in the first quarter of...
XVIVO Perfusion swings to loss in Q1 2019
25 April 2019 - XVIVO Perfusion AB (STO:XVIVO) reported on Wednesday a net loss of SEK0.3m, or SEK0.01 per share, for the first quarter of 2019, from January to March 2019.This was a decline from net ...
Vitrolife's net income up in Q1 2019
24 April 2019 - Vitrolife AB (STO:VITR), an international medical device company, reported on Tuesday net income of SEK86m, or EPS of SEK 0.79, for the first quarter of 2019, from January 2019 to Marc...
TherapeuticsMD Signs Binding Commitment Letter for USD 300m Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
22 April 2019 - - US-based women's healthcare company TherapeuticsMD, Inc. (NASDAQ: TXMD) has signed a binding commitment letter for a fully-negotiated USD 300m non-dilutive secured term loan fin...
Agilent Receives an Expanded FDA Approval for its Companion Diagnostic in NSCLC
22 April 2019 - - The US Food and Drug Administration has updated its approval of US-based Agilent Technologies Inc.'s (NYSE: A) PD-L1 IHC 22C3 pharmDx assay, the company said.

...
Vaxart Doses First Patient in Randomised Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
18 April 2019 - - US-based biotechnology company Vaxart, Inc has started dosing subjects in the randomised cohort of the Phase 1b bivalent norovirus vaccine clinical trial, the company said.